Stock Ratings / Health Care / DRTS / options

BVS (66) PRCT (48) AORT (54) IRMD (68) ⌘ Pro Terminal →

Alpha Tau Medical Ltd. (DRTS) Options Positioning, Max Pain & Unusual Sweeps

$13.23 -0.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.18

Alpha Tau Medical Ltd. (DRTS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.22B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.18 (-0.35%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRTS)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY DRTS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 79% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$14.41-14.7% Next Q

Q2 (-2Q)

Grade E$12.29+7.1% Next Q

Q3 (-1Q)

Grade E$13.16+0.5% Next Q

Current

Grade E$13.23-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRTS currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.26) and Max Pain ($13.89) forces dealer call-delta covering toward $16.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DRTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.7%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DRTS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DRTS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRTS)

✓Walkthrough of DRTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +58.63%▲ ASCENDING CHANNEL

2026-10-30O $12.85H $13.23L $12.70C $13.23VOL 475.3K

RES: $17.19SUP: $12.17SMA50: $14.26SMA200: $10.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRTS Butterfly Map → + Track DRTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRTS)

Health Care Rank #861 of 1016 ⚔️ BVS vs DRTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRTS vs. BVS, PRCT, AORT, IRMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alpha Tau Medical Ltd. (DRTS) ranks #861 by composite RQD confidence (33/100, grade E) and #337 by equity capitalization ($1.22B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with DRTS at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRTS ACTIVE Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	Benchmark Subject
BVS Bioventus Inc. (Class A)	C+	66/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	/bvs-vs-drts →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-drts →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-drts →
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-drts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001871321

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alpha Tau Medical Ltd. (DRTS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$42.6M, operating cash flow of -$26.7M, and free cash flow of -$32.8M (-48.7% YoY). On the balance sheet, DRTS closed FY2025 with $105.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$42.6M	-$26.7M	-$32.8M	$105.7M	—
FY2024 (FY)	2024-12-31	$0	-$31.8M	-$19.8M	-$22.0M	$86.2M	—
FY2023 (FY)	2023-12-31	$0	-$29.2M	-$18.0M	-$18.0M	—	—

3. DRTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alpha Tau Medical Ltd. (NASDAQ: DRTS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $13.23 (-0.90% 1D, market cap $1.22B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DRTS ranks #861 in composite RQD confidence.

How does DRTS compare to BVS and PRCT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DRTS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BVS (Bioventus Inc. (Class A)) holds a C+ grade (66/100 RQD, P/E 55.0x, ROIC 10.4%, cap $1.25B) and PRCT (PROCEPT BioRobotics Corporation) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRTS?

Per DRTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001871321), Alpha Tau Medical Ltd. generated $0 in revenue, -$42.6M in net income, and -$32.8M in free cash flow against $105.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRTS trading relative to its 50-day, 200-day, and 52-week technical levels?

DRTS last traded at $13.23 (-0.90% on volume of 293,585 shares), positioning the stock -7.22% below its 50-day simple moving average ($14.26) and +24.81% above its 200-day simple moving average ($10.60). Across its 52-week range of $3.43 to $15.79, DRTS sits at the 79.3% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($11.95 to $14.51).

DRTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DRTS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DRTS.

Direct Sub-Reports: DRTS RQD Cockpit DRTS 12M Forecast DRTS Earnings & Move DRTS Dividends & DRIP DRTS Insiders & 13F DRTS Whale Options DRTS Profit Sankey DRTS News & Why